Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 10 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Spero Therapeutics Inc | SPRO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 1.26 | 07:36:45 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.26 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 3 | 10 | - | 0.99 - 2.04 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:03:28 | 6 | $ 1.26 | USD |
Spero Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 66.78M | 53.00M | - | 53.51M | -46.42M | -0.88 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Spero Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.14 | 1.31 | 1.14 | 1.25 | 138,155 | 0.12 | 10.53% |
| 1 Month | 1.05 | 1.31 | 1.05 | 1.17 | 165,696 | 0.21 | 20.0% |
| 3 Months | 1.29 | 1.32 | 0.99 | 1.17 | 171,957 | -0.03 | -2.33% |
| 6 Months | 1.78 | 1.82 | 0.99 | 1.38 | 265,238 | -0.52 | -29.21% |
| 1 Year | 1.78 | 2.04 | 0.99 | 1.55 | 376,415 | -0.52 | -29.21% |
| 3 Years | 17.63 | 23.639 | 0.6801 | 2.98 | 961,661 | -16.37 | -92.85% |
| 5 Years | 6.75 | 23.639 | 0.6801 | 3.69 | 627,103 | -5.49 | -81.33% |
Spero Therapeutics Description
| Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |
